Zelira Therapeutics Limited

Zelira Therapeutics (OTCMKTS:ZLDAF) and Hyperion DeFi (NASDAQ:HYPD) Critical Analysis

Zelira secures transformative US$33 million funding for HOPE® 1 autism program

Zelira Therapeutics (OTCMKTS:ZLDAF) Trading Up 13.9% – Here’s Why

Zelira Therapeutics (OTCMKTS:ZLDAF) Trading Down 4.4% – Here’s What Happened

Zelira Therapeutics well placed to generate further growth in cash flow as commercialisation accelerates

Zelira Therapeutics receives A$1.292 million cash R&D tax incentive

Zelira Therapeutics receives 25% of US$1 million licensing fee from DRCN Holdings for EDCDM technology

Zelira Therapeutics' Phase 1 dose escalation study in chronic pain patients on long-term opioid treatment published in peer-reviewed journal

Zelira Therapeutics expands into growing New Zealand cannabinoid-based medicines market

Zelira Therapeutics gets ethics green light for Phase 2a trial of sports injury cannabinoid

Zelira Therapeutics develops enhanced solid-form cannabinoid production method, signs foundational licensing deal

Zelira Therapeutics research-backed products behind its impressive growth

Zelira Therapeutics gains substantial new US-based shareholder following US$5 million cap raise

Zelira Therapeutics set to launch suite of new cannabinoid-based products over FY22 and grow sales of existing products

Zelira™ Launches RAF FIVE™ Acne Treatment Products Through Its Dermatology Focused Subsidiary

Zelira Therapeutics launches RAF FIVE™ CBD acne treatment products

Zelira Therapeutics expands into large German market via exclusive cannabis distribution agreement

Zelira Therapeutics' commercialisation program to see launch of suite of new cannabinoid-based products over FY22

Zelira Therapeutics closes out FY21 with record cash receipts ahead of product launches

Zelira Therapeutics to go head-to-head with big pharma in US clinical pain trial